Trends in Cardiovascular Medicine
Volume 17, Issue 2 , Pages 35-43 , February 2007

Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity

  • Danielle Duffy
    • ,
  • Daniel Rader

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Daniel Rader, The Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania School of Medicine, 654 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA. Tel.: (+1) 215-573-4176; fax: (+1) 215-573-8606.

References 

  1. ARPEGGIO (Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients): n.d. Retrieved October 29, 2006, from http://www.clinicaltrials.gov/ct/show/NCT00288236?order=2.
  2. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63:908–914
  3. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  4. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 1998;8:PL113–PL117
  5. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143:998–1007
  6. Cota D, Marsicano G, Lutz B, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord. 2003;27:289–301
  7. Cota D, Marsicano G, Tschop , et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423–431
  8. CRESCENDO (Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes): n.d. Retrieved October 29, 2006, from http://www.clinicaltrials.gov/ct/show/NCT00263042?order=3.
  9. Croci T, Landi M, Galzin AM, Marini P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol. 2003;140:115–122
  10. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–2134
  11. Despres JP, Lemieux I, Almeras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. Int J Obes (Lond). 2006;30(Suppl 1):S44–S52
  12. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ. 2001;322:716–720
  13. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3:771–784
  14. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822–825
  15. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005;29:1153–1167
  16. Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation. 2006;113:1140–1150
  17. Dunbar RL, Rader DJ. Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?. Minerva Endocrinol. 2004;29:89–111
  18. Eckel RH, York DA, Rossner S, et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation. 2004;110:2968–2975
  19. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444–2449
  20. Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol. 2006;69:471–478
  21. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  22. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  23. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847–2850
  24. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655–1663
  25. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 2005;19:1567–1569
  26. Kirkham TC, Williams CM. Endogenous cannabinoids and appetite. Nutr Res Rev. 2001;14:65–86
  27. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550–557
  28. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  29. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  30. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–546
  31. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond). 2005;29:183–187
  32. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28:385–390
  33. NCEP ATP III . Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143–3421
  34. Nieves DJ, Cnop M, Retzlaff B, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2003;52:172–179
  35. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298–1305
  36. Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G. The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes (Lond). 2006;30(Suppl 1):S33–S38
  37. Pagotto U, Cervino C, Vicennati V, et al. How many sites of action for endocannabinoids to control energy metabolism?. Int J Obes (Lond). 2006;30(Suppl 1):S39–S43
  38. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27:73–100
  39. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA. 2006;295:761–775
  40. Poirier B, Bidouard JP, Cadrouvele C, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab. 2005;7:65–72
  41. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968–976
  42. RAPSODI (Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes): n.d. Retrived October 29, 2006 from http://www.clinicaltrials.gov/ct/show/NCT00325650?order=1.
  43. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol. 2003;284:R345–R353
  44. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28:640–648
  45. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts?. Circulation. 2003;108:1546–1551
  46. Samaha FF, Szapary PO, Iqbal N, et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:624–630
  47. Scheen AJ. Effects of rimonabant in patients with type 2 diabetes mellitus. In: Presented at ADA 2005 Annual Scientific Sessions; San Diego, CA:June 12. 2005;
  48. Siler JF, Sheep WL, Bates LB, et al. Marihuana smoking in Panama. Mil Surg. 1933;73:269–280
  49. STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant–the Intravascular Ultrasound Study): n.d. Retrieved October 29, 2006, from http://www.clinicaltrials.gov/ct/show/NCT00124332?order=1.
  50. Szapary PO, Bloedon LT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:182–188
  51. Trujillo ME, Scherer PE. Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257:167–175
  52. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol. 2004;143:520–523
  53. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397
  54. Vickers SP, Webster LJ, Wyatt A, et al. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl). 2003;167:103–111
  55. VICTORIA (VIsceral Fat Reduction Assessed by CT-Scan On RImonabAnt): n.d. Retrieved October 29, 2006, from http://www.clinicaltrials.gov/ct/show/NCT00299325?order=3.
  56. Williams CM, Kirkham TC. Anandamide induces overeating: Mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl). 1999;143:315–317
  57. Wyszynski DF, Waterworth DM, Barter PJ, et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol. 2005;95:194–198
  58. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–1118

PII: S1050-1738(06)00175-7

doi: 10.1016/j.tcm.2006.11.003

Trends in Cardiovascular Medicine
Volume 17, Issue 2 , Pages 35-43 , February 2007

Article Tools

* Image Usage & Resolution